VA's $1.08B Pharmaceutical Prime Vendor Contract Awarded to McKesson Corporation for FY2025

Contract Overview

Contract Amount: $1,075,377,430 ($1.1B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-08-01

End Date: 2025-08-30

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 AUGUST

Plain-Language Summary

Department of Veterans Affairs obligated $1.08 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 AUGUST Key points: 1. The Department of Veterans Affairs (VA) awarded a significant contract to McKesson Corporation for pharmaceutical prime vendor services. 2. This contract represents a substantial portion of the VA's pharmaceutical spending, highlighting McKesson's dominant position in the market. 3. Potential risks include over-reliance on a single vendor and ensuring competitive pricing over the contract's duration. 4. The healthcare sector relies heavily on such prime vendors for efficient drug distribution.

Value Assessment

Rating: good

The contract value of $1.08 billion for a single month suggests a high volume of pharmaceutical purchases. Benchmarking against similar large-scale pharmaceutical distribution contracts is necessary to fully assess pricing competitiveness.

Cost Per Unit: N/A

Competition Analysis

Competition Level: unknown

The contract type is a delivery order, but the specific procurement method (e.g., full and open competition, sole-source) is not detailed. The impact on price discovery depends heavily on the level of competition exercised.

Taxpayer Impact: The efficient procurement of pharmaceuticals through this contract aims to ensure timely access to medications for veterans, representing a significant taxpayer investment in healthcare.

Public Impact

Ensures access to a wide range of pharmaceuticals for veterans. Supports the VA's mission to provide comprehensive healthcare services. McKesson's role is critical in the pharmaceutical supply chain for the federal government. Potential for cost savings through bulk purchasing and efficient distribution.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

  • Lack of clarity on competition method
  • Potential for price escalation without strong oversight
  • Dependence on a single large vendor

Positive Signals

  • Ensures supply chain continuity for critical medications
  • Leverages established vendor infrastructure
  • Supports a large veteran population's healthcare needs

Sector Analysis

The healthcare sector, particularly pharmaceutical distribution, is characterized by large, established players like McKesson. This contract reflects the significant spending within the VA for essential medicines, aligning with typical benchmarks for large federal healthcare procurements.

Small Business Impact

This contract appears to be awarded to a large prime vendor, suggesting limited direct opportunities for small businesses within this specific award. Subcontracting opportunities may exist but are not detailed here.

Oversight & Accountability

Oversight will be crucial to ensure McKesson meets performance requirements and that pricing remains competitive throughout the contract period. The VA's contracting office is responsible for monitoring this delivery order.

Related Government Programs

  • Department of Veterans Affairs Contracting
  • Department of Veterans Affairs Programs

Risk Flags

  • Vendor Lock-in
  • Price Volatility
  • Supply Chain Disruption Risk
  • Limited Small Business Participation

Tags

department-of-veterans-affairs, delivery-order, billion-dollar

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.08 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 AUGUST

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.08 billion.

What is the period of performance?

Start: 2025-08-01. End: 2025-08-30.

What was the specific procurement method used for this delivery order, and what was the basis for selecting McKesson Corporation?

The provided data does not specify the procurement method. Understanding whether this was a competitive bid, a call against an existing contract, or a sole-source award is crucial for assessing value. If competitive, the number of bidders and the evaluation criteria would inform the fairness of the price. If sole-source, justification for lack of competition is needed.

How does the unit cost of pharmaceuticals under this contract compare to industry benchmarks and previous VA contracts?

A detailed cost-benefit analysis requires comparing the unit prices of key pharmaceuticals procured through this contract against established market rates and historical VA pricing. Variations could indicate successful negotiation, market fluctuations, or potential overpricing, necessitating further investigation into the contract's value proposition.

What mechanisms are in place to ensure McKesson Corporation maintains high service levels and product quality throughout the contract duration?

Effective oversight mechanisms, including performance metrics, regular reviews, and clear remedies for non-performance, are essential. The VA must actively monitor McKesson's adherence to delivery schedules, inventory management, and product integrity to ensure the reliable supply of critical medications to veterans.

More Contracts from Mckesson Corporation

View all Mckesson Corporation federal contracts →

Other Department of Veterans Affairs Contracts

View all Department of Veterans Affairs contracts →

Explore Related Government Spending